Amgen reports positive results for migraine drug erenumab

10 June 2016
2019_biotech_test_vial_discovery_big

Amgen’s (Nasdaq: AMGN) experimental migraine drug erenumab has met the main goal of a midstage study by reducing the number of monthly attacks compared with a placebo.

Erenumab, which is being co-developed with Novartis (VTX: NOVN), was tested at two doses in a 12-week, 667-patient Phase II study of subjects who were experiencing about 18 migraine days a month.

Patients who received either the 70mg or 140mg doses injected once monthly experienced a 6.6-day reduction in monthly migraine days, according to initial results.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology